Solis BioDyne OÜ. (9/1/21). "Press Release: Stephan Goldenbaum Is the New CEO of Biotech Company Solis BioDyne".

	Organisation	Solis BioDyne OÜ
	Organisation 2	Eppendorf AG
	Today	Eppendorf SE
	Group	Eppendorf (Group)
	Product	DNA polymerase
	Product 2	PCR reagents
	Person	Goldenbaum, Stephan (Solis BioDyne 202109– CEO before Eppendorf + Qiagen)
	Person 2	Essakali, Salim (Qiagen 202409– Head of Strategic Partnerships + OEM divsiion before Solis BioDyne + Boston Scientific)

Starting form 1 September, Stephan Goldenbaum will start work as the CEO of Solis BioDyne, one of Estonia’s leading biotech companies. Current CEO Priit Karjus will continue as a Supervisory Board member.

Stephan Goldenbaum has worked in biotech since 2003. Until 2017, he was head of sales in Europe, Africa and the Middle East working for QIAGEN, a leading global biotech company. From 2018 until joining Solis BioDyne, Goldenbaum worked on developing sales channels in the large Germany-based biotech company Eppendorf Group. Goldenbaum holds Master’s degrees in biology and business integration.

According to Stephan Goldenbaum, he considers his task to be the improvement of Solis BioDyne’s product development and sales, growing the company’s export volumes and expanding its network of partnerships. “We operate in the market of reagents, where export volumes are measured in millilitres. This means even more work needs to be done in research and development, that drives export. We want to work even more closely with research institutions, primarily the University of Tartu with whom we already have close relations. Solis BioDyne wants to continue to be one of the most attractive employers in Estonia for students and scientists of life-sciences. For example, we are very interested in recruiting people trained in biotechnology, chemistry, gene technology and bioanalytics,” says Goldenbaum.

Solis BioDyne is also preparing to build a larger and more modern new office and production building on Palsa Street in Tartu. “We are starting to outgrow our current premises in Tartu Science Park because our staff and production volumes have multiplied over the past couple of years. We hope to move into the new building equipped with a state-of-the-art biotech research and development unit in a year’s time,” explains Goldenbaum.

Salim Essakali, who also has long-term experience from the biotechnology company QIAGEN and the manufacturer of medical devices Boston Scientific, will also start working as the Head of Global Sales and Marketing of Solis BioDyne on September 1. 2021.

He has conducted his Master of Science in Molecular Pathology, holds an MBA in Corporate Strategy, and has extensive management experience developing, commercializing, and life-cycle-managing in BioTech and MedTech field.

OÜ Solis BioDyne operating in Tartu Science Park is one of Estonia’s leading biotech companies developing and producing reagents. DNA polymerases, PCR Master Mixes, qPCR Mixes and reverse transcription reagents are highly valued across the globe. Majority of its exports end up in Europe and the United States of America. Solis BioDyne uses unique genetic modification within all products to make them stable at room temperature for 30 days, to provide more sustainable and cost-effective solutions. The company was established in 1995 and now employs over 60 people.

Further information:

Sigrid Hänni
Marketing and Communication Manager
SOLIS BIODYNE OÜ
A: Teaduspargi 9, 50411 Tartu, Estonia
T: +372 5682 5751
E: [email protected]
W: www.solisbiodyne.com

Record changed: 2023-06-05

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]